Quantcast
Home > Quotes > CLBS

Caladrius Biosciences, Inc. Common Stock (CLBS) Quote & Summary Data

CLBS 
$3
*  
0.10
3.23%
Get CLBS Alerts
*Delayed - data as of May 17, 2019  -  Find a broker to begin trading CLBS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CLBS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
6.875
Today's High / Low
$ 3.16 / $ 2.84
Share Volume
24,155
50 Day Avg. Daily Volume
29,866
Previous Close
$ 3.10
52 Week High / Low
$ 11.65 / $ 2.77
Market Cap
31,146,696
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.47

Intraday Chart

Shares Traded

Share Volume:
24,155
50 Day Avg. Daily Volume:
29,866

Trading Range

The current last sale of $3 is 8.30% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.16 $ 11.65
 Low: $ 2.84 $ 2.77

Company Description (as filed with the SEC)

Caladrius Biosciences, Inc. ("we," "us," "our," "Caladrius" or the "Company") is a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular medicine and cell therapy, among other areas. Our goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, in Phase 2 and eligible for early conditional approval in Japan for the treatment of critical limb ischemia ("CLI"); CLBS14-CMD, in Phase 2 in the U.S.  ... More ...  



Risk Grade

Where does CLBS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 3.10
Open Date:
May 17, 2019
Close Price:
$ 3
Close Date:
May 17, 2019


Consensus Recommendation

Analyst Info